Response to the Letter to the Editor by Dr. Srinivas on the recent publication of Al-Tawil et al. on the pharmacokinetics of transdermal buprenorphine patch in the elderly by Helen Johnson & Anna-Carin Berggren
LETTER TO THE EDITORS
Response to the Letter to the Editor by Dr. Srinivas on the recent
publication of Al-Tawil et al. on the pharmacokinetics
of transdermal buprenorphine patch in the elderly
Helen Johnson & Anna-Carin Berggren
Received: 28 February 2013 /Accepted: 18 March 2013 /Published online: 16 April 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
To the Editor,
We are writing in response to the letter from Dr.
Srinivas commenting on the recent publication by Al-
Tawil et al. on the pharmacokinetics of transdermal
buprenorphine patch in the elderly [1]. We represent
the authors and Mundipharma Research Ltd., the Clini-
cal Pharmacology group of which, Helen Johnson (a co-
author) in particular, was responsible for the pharmaco-
kinetic analysis carried out in this study.
The study reported comparable systemic exposures of
buprenorphine and norbuprenorphine in two groups of
elderly (≥ 75 years) and younger (50–60 years) individ-
uals, leading to the conclusion that no dosage alterations
are necessary for pharmacokinetic (PK) reasons when
treating elderly people with buprenorphine transdermal
patches. We are surprised that Dr. Srinivas has elected
to extrapolate from the average PK data that were
reported in the article, based on the qualitatively (but
not significantly) higher norbuprenorphine plasma con-
centrations in the elderly group, and subsequently to
speculate that this may contribute to several safety is-
sues, including respiratory depression.
In response, we wish to provide a more detailed
illustration of the data generated in this study. The
following figures illustrate the distribution of individual
subject area under the curve values associated with
buprenorphine and norbuprenorphine in the two study
groups (Figs. 1 and 2).
These figures demonstrate very clearly that the
ranges of exposure of both compounds were highly
comparable between the groups, and illustrate why
there were no significant differences recorded, or even
hinted at, in the original analysis. The spread and
overlap of individual Cmin and Cmax steady state data
are also comparable between the two groups for both
analytes, further reinforcing the primary conclusion. As
stated in the original article, more adverse events (216)
were actually recorded in the younger group than in
elderly participants (164).
Fig. 1 Area under the plasma concentration-time curve at steady state
(AUCtau) buprenorphine, data points are individual participant values
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We have provided the data in more detail to support the
original scientific findings. In so doing, we believe that we
have demonstrated that there is no basis for the speculative
text regarding norbuprenorphine and its safety profile in the
elderly.
Yours sincerely,
Helen E Johnson (Clinical Pharmacokineticist) and
Anna-Carin Berggren (Medical Affairs Manager).
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
Al-Tawil N, Odar-Cederlöf I, Berggren A-C, Johnson HE (2013)
Pharmacokinetics of transdermal buprenorphine patch in the el-
derly. Eur J Clin Pharmacol 69:143–149
Fig. 2 Area under the plasma concentration-time curve at steady state
(AUCtau) norbuprenorphine, data points are individual participant values
1610 Eur J Clin Pharmacol (2013) 69:1609–1610
